Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $69.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 20.66% year-over-year to $69.9 million; the TTM figure through Mar 2026 stood at $69.9 million (down 20.66% YoY), while the FY2025 annual figure was $72.3 million, down 21.71% from the prior year.
• Total Non-Current Liabilities was $69.9 million for Q1 2026 at Zentalis Pharmaceuticals, down from $72.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $112.5 million in Q4 2023 to a low of $45.0 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $90.1 million across 5 years, with a median of $95.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 163.56% in 2022, then decreased 28.98% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $102.7 million in 2022, then gained by 9.6% to $112.5 million in 2023, then declined by 17.97% to $92.3 million in 2024, then fell by 21.71% to $72.3 million in 2025, then fell by 3.29% to $69.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $69.9 million (Q1 2026), $72.3 million (Q4 2025), and $73.9 million (Q3 2025), per Business Quant data.